(Q37489013)

20 August 2017

Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A. (English)

1 reference

20 August 2017

0 references

Coagulation factor VIII

0 references

0 references

6

Ingrid Pabinger

1 reference

20 August 2017

0 references

Johnny Mahlangu

1

1 reference

20 August 2017

Jerry S Powell

2

1 reference

20 August 2017

Margaret V Ragni

3

1 reference

20 August 2017

Pratima Chowdary

4

1 reference

20 August 2017

Neil C Josephson

5

1 reference

20 August 2017

Hideji Hanabusa

7

1 reference

20 August 2017

Naresh Gupta

8

1 reference

20 August 2017

Roshni Kulkarni

9

1 reference

20 August 2017

Patrick Fogarty

10

1 reference

20 August 2017

David Perry

11

1 reference

20 August 2017

Amy Shapiro

12

1 reference

20 August 2017

K John Pasi

13

1 reference

20 August 2017

Shashikant Apte

14

1 reference

20 August 2017

Ivan Nestorov

15

1 reference

20 August 2017

Haiyan Jiang

16

1 reference

20 August 2017

Shuanglian Li

17

1 reference

20 August 2017

Srividya Neelakantan

18

1 reference

20 August 2017

Lynda M Cristiano

19

1 reference

20 August 2017

Jaya Goyal

20

1 reference

20 August 2017

Jurg M Sommer

21

1 reference

20 August 2017

Jennifer A Dumont

22

1 reference

20 August 2017

Nigel Dodd

23

1 reference

20 August 2017

Karen Nugent

24

1 reference

20 August 2017

Gloria Vigliani

25

1 reference

20 August 2017

Alvin Luk

26

1 reference

20 August 2017

Aoife Brennan

27

1 reference

20 August 2017

Glenn F Pierce

28

1 reference

20 August 2017

A-LONG Investigators

29

1 reference

20 August 2017

language of work or name

English

0 references

publication date

13 November 2013

1 reference

20 August 2017

1 reference

20 August 2017

123

1 reference

20 August 2017

3

1 reference

20 August 2017

317-325

1 reference

Fc-fusion proteins and FcRn: structural insights for longer-lasting and more effective therapeutics

20 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3894491

F8 gene mutation type and inhibitor development in patients with severe hemophilia A: systematic review and meta-analysis

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3894491

Safety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia A patients

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3894491

A randomized comparison of two prophylaxis regimens and a paired comparison of on-demand and prophylaxis treatments in hemophilia A management

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3894491

Improvements in factor concentrates

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3894491

Rational design of a fully active, long-acting PEGylated factor VIII for hemophilia A treatment

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3894491

Factor VIII and von Willebrand factor interaction: biological, clinical and therapeutic importance

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3894491

FcRn: the neonatal Fc receptor comes of age.

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3894491

Prolonged activity of a recombinant factor VIII-Fc fusion protein in hemophilia A mice and dogs

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3894491

Biological rationale for new drugs in the bleeding disorders pipeline

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3894491

Antibody formation and specificity in Bethesda-negative brother pairs with haemophilia A.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3894491

Clinical evaluation of moroctocog alfa (AF-CC), a new generation of B-domain deleted recombinant factor VIII (BDDrFVIII) for treatment of haemophilia A: demonstration of safety, efficacy, and pharmacokinetic equivalence to full-length recombinant fa

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3894491

Randomized, controlled, parallel-group trial of routine prophylaxis vs. on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A (SPINART).

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3894491

Biochemical and functional characterization of a recombinant monomeric factor VIII-Fc fusion protein

26 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3894491

The Italian AICE-Genetics hemophilia A database: results and correlation with clinical phenotype

26 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3894491

A shorter von Willebrand factor survival in O blood group subjects explains how ABO determinants influence plasma von Willebrand factor

26 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3894491

Long-term anti-FVIII antibody response in Bethesda-negative haemophilia A patients receiving continuous replacement therapy

26 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3894491

Enhancing the pharmacokinetic properties of recombinant factor VIII: first-in-human trial of glycoPEGylated recombinant factor VIII in patients with hemophilia A.

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3894491

Factor VIII products and inhibitor development in severe hemophilia A.

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3894491

Distinct characteristics of antibody responses against factor VIII in healthy individuals and in different cohorts of hemophilia A patients.

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3894491

Clinical trial design in haemophilia

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3894491

F8 and F9 mutations in US haemophilia patients: correlation with history of inhibitor and race/ethnicity

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3894491

FDA Workshop on factor VIII inhibitors held at the NIH, Bethesda, MA on 21 November 2003.

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3894491

Barriers to compliance with prophylaxis therapy in haemophilia

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3894491

10.1182/BLOOD-2013-10-529974

2 September 2018

Identifiers

DOI

1 reference

20 August 2017

1 reference

20 August 2017

PubMed publication ID

24227821

1 reference